naa a22 4500 510764371 CHVBK 20180411083151.0 cr unu---uuuuu 180411e20130201xx s 000 0 eng 10.1007/s12094-012-0928-6 doi (NATIONALLICENCE)springer-10.1007/s12094-012-0928-6 The role of annexin A3 playing in cancers [Elektronische Daten] [Na Wu, Shuqing Liu, Chunmei Guo, Zhijie Hou, Ming-Zhong Sun] Annexin family proteins are a well-known multigene family of Ca2+-regulated phospholipid- and membrane-binding proteins. As one of the annexin family genes/proteins, accumulated researches have begun to reveal that annexin A3 (Anxa3) exhibits important roles in tumor development, metastasis and drug resistance. The summarized research evidences in recent years indicate Anxa3 might specifically functionalize either as a tumor suppressor or as a tumor promoter candidate for different cancers depending on the types of tumor cells and tissues. The up-regulation of Anxa3 was found to be correlated with enhanced drug resistance of ovarian cancer, to promote the developments of colorectal adenocarcinoma and pancreatic carcinoma, and to facilitate the metastases of lung adenocarcinoma and hepatocarcinoma; meanwhile, the decreased Anxa3 expressions was negatively correlated with the developments of prostatic carcinoma and renal carcinoma. It is conceivable that Anxa3 could be regarded as a target for therapeutic intervention and a biological indicator for tumor development, invasion and metastasis as well as for the prognosis of tumor patients. Federación de Sociedades Españolas de Oncología (FESEO), 2012 Annexin A3 nationallicence Cancer nationallicence Development nationallicence Metastasis nationallicence Drug resistance nationallicence Wu Na Department of Biotechnology, Dalian Medical University, 116044, Dalian, China aut Liu Shuqing Department of Biochemistry and Molecular Biology, Dalian Medical University, 116044, Dalian, China aut Guo Chunmei Department of Biotechnology, Dalian Medical University, 116044, Dalian, China aut Hou Zhijie Department of Biotechnology, Dalian Medical University, 116044, Dalian, China aut Sun Ming-Zhong Department of Biotechnology, Dalian Medical University, 116044, Dalian, China aut Clinical and Translational Oncology Springer Milan 15/2(2013-02-01), 106-110 1699-048X 15:2<106 2013 15 12094 https://doi.org/10.1007/s12094-012-0928-6 text/html Onlinezugriff via DOI 1 review-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s12094-012-0928-6 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Wu Na Department of Biotechnology, Dalian Medical University, 116044, Dalian, China aut NATIONALLICENCE 700 1- Liu Shuqing Department of Biochemistry and Molecular Biology, Dalian Medical University, 116044, Dalian, China aut NATIONALLICENCE 700 1- Guo Chunmei Department of Biotechnology, Dalian Medical University, 116044, Dalian, China aut NATIONALLICENCE 700 1- Hou Zhijie Department of Biotechnology, Dalian Medical University, 116044, Dalian, China aut NATIONALLICENCE 700 1- Sun Ming-Zhong Department of Biotechnology, Dalian Medical University, 116044, Dalian, China aut NATIONALLICENCE 773 0- Clinical and Translational Oncology Springer Milan 15/2(2013-02-01), 106-110 1699-048X 15:2<106 2013 15 12094 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer